FY2025 EPS Estimates for CMPS Boosted by Cantor Fitzgerald

COMPASS Pathways plc (NASDAQ:CMPS) – Equities research analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for COMPASS Pathways in a report released on Monday, May 12th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings of ($1.91) per share for the year, up from their prior forecast of ($2.00). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share.

A number of other research firms have also commented on CMPS. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of COMPASS Pathways in a research note on Monday. Stifel Nicolaus started coverage on shares of COMPASS Pathways in a report on Thursday, February 27th. They set a “buy” rating and a $11.00 price target for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th. Finally, Canaccord Genuity Group lowered their target price on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, COMPASS Pathways has a consensus rating of “Buy” and a consensus target price of $20.20.

COMPASS Pathways Price Performance

NASDAQ:CMPS opened at $3.90 on Wednesday. COMPASS Pathways has a 52 week low of $2.49 and a 52 week high of $8.54. The firm’s 50-day simple moving average is $3.34 and its 200 day simple moving average is $3.99. The firm has a market cap of $362.12 million, a price-to-earnings ratio of -1.77 and a beta of 2.27. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.03.

Institutional Trading of COMPASS Pathways

Several hedge funds have recently modified their holdings of the stock. Affinity Asset Advisors LLC boosted its position in shares of COMPASS Pathways by 183.0% during the 4th quarter. Affinity Asset Advisors LLC now owns 850,512 shares of the company’s stock worth $3,215,000 after purchasing an additional 550,000 shares in the last quarter. Barclays PLC grew its stake in COMPASS Pathways by 2.1% in the 4th quarter. Barclays PLC now owns 419,194 shares of the company’s stock valued at $1,585,000 after purchasing an additional 8,718 shares during the period. Geode Capital Management LLC grew its position in COMPASS Pathways by 160.3% during the third quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock valued at $266,000 after buying an additional 25,970 shares during the period. Hennion & Walsh Asset Management Inc. increased its stake in shares of COMPASS Pathways by 18.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 174,921 shares of the company’s stock worth $661,000 after purchasing an additional 26,787 shares during the last quarter. Finally, Altium Capital Management LLC purchased a new stake in COMPASS Pathways in the fourth quarter worth $5,384,000. Institutional investors own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.